Source comparison
Side-by-Side Comparison
Class Synthetic Fragment Thymosin Peptide FDA Status Research Use Primary Uses Tissue Repair, Recovery Tissue Repair, Recovery, Anti-Inflammation Administration Subcutaneous Injection Typical Dosing 200–1,000 mcg/day subcutaneous, most commonly 500 mcg/day 4–8
This comparison does not assign a generated winner or score.
- Class
- Synthetic Fragment
- Thymosin Peptide
- FDA Status
- Research Use
- Primary Uses
- Tissue Repair, Recovery
- Tissue Repair, Recovery, Anti-Inflammation
- Administration
- Subcutaneous Injection
- Typical Dosing
- 200–1,000 mcg/day subcutaneous, most commonly 500 mcg/day
- 4–8 mg/week (initial phase) or 500–1,000 mcg/day; maintenance 2–6 mg/month
- Evidence Level
- —
- Common Side Effects